Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Smart radiation: daily adjustments may spare prostate cancer patients from side effects

NCT ID NCT07276438

First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 29 times

Summary

This trial tests whether using daily MRI or CT scans to adjust radiation plans in real time can lower side effects for men with localized prostate cancer. 186 participants will receive standard stereotactic body radiation therapy (SBRT) either with or without daily plan adaptation. The main goal is to see if fewer men experience urinary problems within 90 days of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UCLA / Jonsson Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90095, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Stereotactic body radiation therapy (SBRT) with daily image-guided adaptation

What this could lead to

If successful, this approach could reduce urinary and bowel side effects from radiation therapy for prostate cancer, making treatment safer and more comfortable.

What could go wrong

This is an early-stage trial focused on side effects, not cure rates. The daily adaptation process is complex and may not significantly improve outcomes for all patients.

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.